Isotechnika, Roche sign $215mm Canadian drug development deal
Executive Summary
Isotechnika (develops immunosuppressives and autoimmune disease therapeutics) has licensed Roche exclusive worldwide marketing rights to its transplant drug candidate ISA (TX) 247.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice